Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Promising MRD negativity rates achieved in a trial of weekly KRd-D in myeloma

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, FL, discusses the results of a Phase II trial (NCT03290950) of weekly carfilzomib, lenalidomide and dexamethasone therapy in combination with daratumumab (wKRd-D) in newly diagnosed multiple myeloma. Patients were treated with 8 cycles of wKRd-D and assessed for measurable residual disease (MRD) with bone marrow samples. The results from the trial are promising, in particular the MRD negativity rates. Adverse events were in line with those seen for the standard of care (KRd). Additionally, at a median follow-up of 10 months, none of the MRD negative patients have progressed. In light of these results, a large, randomized study will be conducted (ADVANCE), comparing wKRd-D to the established standard of care in myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Consultancy: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Honoraria: Adaptive, Amgen, Janssen, Glenmark, Celgene, Binding Site, BMS, Cellectis, Juno, Pfizer
Research Funding: Amgen, Janssen, Takeda, Glenmark, Celgene, Seattle Genetics, Karyopharma
Independent Data Monitoring Committees for clinical trials: Janssen, Takeda
Other: Merck